Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

Martijn W.C. Verbeek, Chiara Buracchi, Anna Laqua, Stefan Nierkens, Lukasz Sedek, Juan Flores-Montero, Mattias Hofmans, Elaine Sobral de Costa, Michaela Nováková, Ester Mejstrikova, Susana Barrena, Saskia Kohlscheen, Monika Szczepanowski, Jan Kulis, Elen Oliveira, Romana Jugooa, Anja X. de Jong, Tomasz Szczepanski, Jan Philippé, Jacques J.M. van DongenAlberto Orfao, Monika Brüggemann, Giuseppe Gaipa, Vincent H.J. van der Velden

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

Original languageEnglish
Pages (from-to)76-81
Number of pages6
JournalBritish Journal of Haematology
Volume197
Issue number1
DOIs
Publication statusPublished - Apr 2022

Keywords

  • acute leukaemia
  • diagnostic haematology
  • flow cytometry
  • minimal residual disease
  • Neoplasm, Residual
  • Adaptor Proteins, Signal Transducing
  • Antigens, CD19/therapeutic use
  • Humans
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
  • Flow Cytometry/methods
  • Burkitt Lymphoma
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

Fingerprint

Dive into the research topics of 'Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study'. Together they form a unique fingerprint.

Cite this